恩他卡朋对帕金森病患者血清氧化应激指标、β-内啡肽及亮脑啡肽水平的影响机制探讨

Effects of entacapone on serum oxidative stress indexes in patients with Parkinson's diseaseβ-Mechanism of endorphin and leuenkephalin levels

目的:探究恩他卡朋对帕金森病患者的治疗效果及对β-内啡肽、亮脑啡肽及血清氧化应激指标的影响。方法:选取我科113例帕金森病患者,以抽签法分组。对照组56例给予左旋多巴治疗,观察组57例给予联合恩他卡朋治疗,对比两组患者帕金森评分、血清氧化应激指标、脑啡肽水平及不良反应发生情况。结果:治疗后观察组帕金森评分量表-Ⅱ(Unified Parkinson disease rating scale-Ⅱ,UPDRS-Ⅱ)、帕金森评分量表-Ⅲ(Unified Parkinson disease rating scale-Ⅲ,UPDRS-Ⅲ)评分、活性氧(Reative oxgen species,ROS)、丙二醛(Malondialdehyde,MDA)水平低于对照组,还原型谷胱甘肽(Glutahone,GSH)、超氧化物歧化酶(Superoxide Dismutase,SOD)、β-内啡肽、亮脑啡肽水平高于对照组(P<0.05)。两组患者不良反应发生率无统计学意义(P>0.05)。结论:恩他卡朋联合左旋多巴对帕金森病患者治疗,可有效降低氧化应激反应,调节脑啡肽水平,改善运动功能和日常生活能力,促进疾病康复,安全性高。

Objective:To investigate the therapeutic effect of entacarbon on patients with Parkinson's disease and its effects onβ-endorphin,enkephalin and serum oxidative stress indexes.Methods:113 patients with Parkinson's disease were divided into groups by drawing lots.Fifty-six patients in the control group were treated with levodopa,and 57 patients in the observation group were treated with entacabone.Parkinson's score,serum oxidative stress index,enkephalin level and the occurrence of adverse reactions were compared between the two groups.Results:After treatment,observation group Parkinson disease rating Scale-Ⅱ(Unified Parkinson Disease rating Scale-Ⅱ,UPDRS-Ⅱ),Parkinson disease rating scale-Ⅲ Unified Parkinson disease rating Scale-Ⅲ,UPDRS-Ⅲ,reative oxgen species(ROS)and Malondialdehyde(MDA)levels were lower than those of control group.The levels of Glutahone(GSH),Superoxide Dismutase(SOD),β-endorphin and enkephalin were higher than those in control group(P<0.05).There was no statistical significance in the incidence of adverse reactions between 2 groups(P>0.05).Conclusion:Entacapone combined with levodopa can effectively reduce oxidative stress response,regulate enkephalin level,improve motor function and daily living ability,and promote rehabilitation of Parkinson's disease with high safety.